CRVO CervoMed Inc.
USHealthcareAs of 2026-07-09 16:00
Why CRVO matters now
CervoMed Inc. (CRVO) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.74 with +9.68% on the session and $34.6M in market capitalization; recent performance reads 1-month +46.71% and YTD -46.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.0M, and EPS of $-0.86. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -70.2%.
The latest indexable market news headline is "CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes BOGER JOSHUA S filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.70
P/S
121.70
EV/EBITDA
-1.04
DCF Value
$0.80
FCF Yield
-70.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-9642.1%
Net Margin
-9311.6%
ROE
-136.1%
ROA
-198.7%
ROIC
-293.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.0M | $-0.86 |
| Q4 2025 | $0.00 | $-8.1M | $-0.87 |
| FY 2025 | $0.00 | $-27.0M | $-2.98 |
| Q3 2025 | $322.6K | $-7.7M | $-0.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$9.00 - $9.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-4.54
CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.